Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Inclusion Criteria

• •1. Patients who received glofitamab according to Compassionate Use Program AG42296
• •2. Age \> 18 years
• •3. Patients who received at least one dose of glofitamab between March 2022 and September 2023 in the context of the compassionate use program and who completed at least 1 year of observation after last glofitamab administration unless the patient died or was lost to follow up
• •4. Patients who provided their consent according to local regulation to collect their data for study purposes, dead patients or patients lost to follow up for which any attempt has been made to collect their consent, according to local regulation on data privacy